ROLE OF GSK-3 IN Wnt/β-CATENIN SIGNALING PATHWAY IN OBESITY

The complexity of the adipogenesis mechanism results from the impact of multiple cues, among which an important place is held by the components of the Wnt signaling pathway. The search for potential markers of the development of diseases related to obesity aroused an interest in the study of GSK-3 (glycogen synthase kinase), β-catenin. GSK-3β is an intracellular serine / threonine kinase found in the cytoplasm, nucleus, mitochondria, synthesized in all body tissues and involved in regulating metabolic processes, cell proliferation, apoptosis etc. The first of the discovered functions of GSK-3β was the regulation of glycogen synthesis. Active GSK-3β phosphorylates and thereby inhibits glycogen synthase. As a result of the insulin binding to the cell receptor via inositol-3-phosphate, protein kinase B (Akt1) is activated, which, in turn, phosphorylates and inhibits GSK-3β. In addition, GSK-3β is involved in the regulating glucose metabolism. The most important function of GSK-3β is the inhibition of the β-catenin protein. In a resting cell, GSK-3β in complex with the APC and Axin proteins binds and phosphorylates the β-catenin transcription factor, which leads to its ubiquitination and degradation. When Wnt proteins act on the cell, the Dvl protein is activated, which, by binding to GSK-3β, releases β-catenin, preventing its degradation, however, the role of GSK3α/β in the adipocyte inflammatory response has not yet been fully investigated, therefore it seems promising to study the role of GSK-3 in the Wnt/β-catenin signaling pathway in obesity

The aim of the study was to assess the activity of the components of the Wnt signaling pathway in obese patients by measuring the serum level of GSK-3 and β-catenin. There were enrolled 32 patients with progressive forms of I-III degree obesity in the absence of diabetes mellitus. The concentration of serum GSK-3α, GSK-3β, and β-catenin was measured by enzyme-linked immunoassay. Data are presented as absolute and relative (%) number of patients; arithmetic mean; medians, 1 and 3 quartiles – Ме (Q0.25-Q0.75). Obese patients contained a 7.5-fold increased serum level of GSK-3α (785 (371-1317.5) pg/ml) compared to healthy individuals 105 (102.5-110) pg/ml, (p < 0.001), paralleled with increased amount of GSK-3β, which level in obese patients was 295 (190-695) pg/ml, which is by 18.3% higher than those in healthy individuals 241 (218.75-287.5) pg/ml, p = 0.111. Amount of GSK-3 depending on the degree of obesity tended to increase, most often coupled to decreased β-catenin level which is consistent with the literature data and can be considered as a prognostic criterion for the course of pathological processes in obesity. 

1. Ackers I., Malgor R. Interrelationship of canonical and non-canonical Wnt signalling pathways in chronic metabolic diseases. Diabetes Vasc. Dis. Res., 2018, Vol. 15, no. 1, pp. 3-13.

2. Ahmad B., Serpell C.J., Fong I.L., Wong E.H. Molecular Mechanisms of Adipogenesis: The Anti-adipogenic Role of AMP-Activated Protein Kinase. Front. Mol. Biosci., 2020, no. 7, 76. doi: 10.3389/fmolb.2020.00076.

3. Beurel E., Grieco S.F, Jope R.S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol. Ther., 2015, no. 148, pp. 114-131.

4. Cawthorn W.P., Bree A.J., Yao Y., Du B., Hemati N., Martinez-Santibañez G., MacDougald O.A. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a β-catenin-dependent mechanism. J. Bone, 2012, Vol. 50, no. 2, pp. 477-489.

5. Chen D., Xie R., Shu B., Landay A. L. Wei C., Reiser J., Spagnoli A., Torquati A., Forsyth C.B., Keshavarzian A., Sumner D.R. Wnt signaling in bone, kidney, intestine, and adipose tissue and inter-organ interaction in aging. Ann. N. Y. Acad. Sci., 2019, Vol. 1442, no. 1, pp. 48-60.

6. Christodoulides C. Lagathu C., Sethi J.K., Vidal-Puig A. Adipogenesis and WNT signaling. Trends Endocrinol. Metab., 2009, Vol. 20, no. 1, pp. 16-24.

7. Cline G.W., Johnson K., Regittnig W., Perret P., Tozzo E., Xiao L., Damico C., Shulman G.I. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (falfa) rats. Diabetes, 2002, Vol. 51, no. 10, pp. 2903-2910.

8. Colomiere M., Permezel M., Lappas M. Diabetes and obesity during pregnancy alter insulin signalling and glucose transporter expression in maternal skeletal muscle and subcutaneous adipose tissue. J. Mol. Endocrinol., 2010, Vol. 44, no. 4, pp. 213-223.

9. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci., 2003. Vol. 116, no. 7, pp. 1175-1186.

10. Lappas M. Is increased in adipose tissue and skeletal muscle from women with gestational diabetes where it regulates the inflammatory response. PLoS One, 2014, Vol. 9, no. 12, e115854. doi: 10.1371/journal.pone.0115854.

11. Markussen L.K., Winther S., Wicksteed B., Hansen J.B. GSK3 is a negative regulator of the thermogenic program in brown adipocytes. Sci. Rep., 2018, Vol. 8, no. 1, 3469. doi: 10.1038/s41598-018-21795-y.

12. Ng L.F., Kaur P., Bunnag N., Suresh J., Sung I., Tan Q.H., Gruber J., Tolwinski N.S. WNT Signaling in Disease. Cells, 2019, Vol. 8, no. 8, pp. 826-857.

13. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. J. Pharmacol., 2009, Vol. 156, no. 6, pp. 885-898.

14. Shen H.H., Yang C.Y., Kung C.W., Chen S.Y., Wu H.M., Cheng P.Y., Lam K.K., Lee Y.M. Raloxifene inhibits adipose tissue inflammation and adipogenesis through Wnt regulation in ovariectomized rats and 3T3-L1 cells. J. Biomed. Sci., 2019, Vol. 26, no. 62.

15. Wang L., Li X., Wang Y. GSK3β inhibition attenuates LPS-induced IL-6 expression in porcine adipocytes. Sci. Rep., 2018, Vol. 8, no. 1, e15967. doi: 10.1038/s41598-018-34186-0.